2025年3月12日 · Progressive supranuclear palsy (PSP) is a rare neurological disorder that affects body movements, walking and balance, and eye movements. PSP is caused by damage to nerve cells in areas of the brain that control thinking and body movements.

Drugs with disease-modifying potential, targeting mechanisms implicated in the disease's pathogenesis are currently tested in Phase 1 and 2 trials. If proven efficacious, these compounds might provide substantial benefits not only to patients with PSP but to patients with other tauopathies as well.

2024年9月3日 · A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder that usually kills within seven years after symptoms start.

2023年12月25日 · Progressive Supranuclear Palsy (PSP) is a rare progressive, fatal neurodegenerative 4-repeat tauopathy. AZP2006 (INN: Ezeprogind) is a first-in-class disease-modifying oral small molecule acting via its strong binding to the complex Progranulin (PGRN) / Prosaposin (PSAP), able to increase the circulating contents of PGRN (plasma and brain) in ...

2023年5月23日 · Progressive supranuclear palsy (PSP) is a rare neurological condition that affects movement, balance, speech, vision, and cognition. It is caused by the degeneration of brain cells, leading to an accumulation of a protein called tau. PSP shares similar symptoms with Parkinson's disease, but it progresses more rapidly a

2024年5月14日 · PSP is universally fatal, and effective disease-modifying therapies for PSP have not yet been identified. Several tau-targeting treatment modalities, including vaccines, monoclonal antibodies, and microtubule-stabilizing agents, have been investigated and have had no efficacy.

2025年1月14日 · New opportunities are emerging for patients with progressive supranuclear palsy (PSP). CurePSP is partnering with the University of California San Francisco (UCSF), a CurePSP Center of Care, on a new platform clinical trial that will test three drugs concurrently, and could include more, bringing new hope for patients with PSP.

Despite exciting new knowledge on the pathophysiology of PSP, there is still no highly effective symptomatic or disease-modifying treatment. We review the evidence on pharmacotherapy and experimental therapies in PSP and provide levels of recommendation for the off-label use of commonly used drugs in this disorder.

Levodopa (with a peripheral decarboxylase inhibitor such as carbidopa or benserazide) is the principal pharmacologic agent used for dopaminergic replacement therapy in PSP, with a more robust response generally seen in the PSP-Parkinsonism (PSP-P) subtype.

2024年9月26日 · Robust gene expression research in humans, mice, and fruit flies has revealed three potential drug targets for progressive supranuclear palsy (PSP). Scientists used systems biology approaches — methods of studying how all the parts of a living organism work together — to identify potential therapeutic strategies based on changes in gene ...